Human Immune System Mice

HUMAN iMMUNE SYSTEM MICE

huHSC-NCG-hIL15

Type : CD34+ Humanized Mice
Strain Number : T038070
Background Strain: NCG-hIL15 [T004886]

STRAIN DESCRIPTION

HuHSC-NCG-hIL15 Mice are NCG-hIL15 [T004886] mice engrafted with cord blood human CD34⁺ hematopoietic stem cells (CD34+ HSC). This strain is genetically modified to express human interleukin-15 (hIL-15), a cytokine essential for the development, survival, and activation of natural killer (NK) cells and memory CD8⁺ T cells. Following transplantation with human CD34⁺ HSC, the huHSC-NCG-hIL15 mice support robust engraftment, expansion differentiation and persistence of functional NK cells.

Features of HuHSC-NCG

1.Functional human Immune cell subsets (T, B and myeloid) with enhanced NK cell development and function.

2.Minimal 20% hCD45  in peripheral blood

3.Stable engraftment and long Lifespan > 39 weeks

4.Customizable :

  • huHSC-NCG-hIL15  for NK-T interaction and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) assessment
  • huHSC-NCG-M  for T-cell and Myeloid dependent Efficacy studies
  • HLA partially matching for cells and tissue transplantation
APPLICATIONS

Oncology and Immuno-oncology e.g : ADCC, Car-NK

Immunology & Inflammation

Infectious Diseases

Autoimmune Diseases

Fig 1: Survival and weight changes in mice post CD34+ HSC engraftment

Fig 2: Immune cell reconstitution in peripheral blood of huHSC-NCG and huHSC-NCG-hIL15 mice.

Peripheral blood was collected at weeks 7, 9, 11, and 13 post-engraftment and analyzed by flow cytometry to assess immune cell development in huHSC-NCG and huHSC-NCG-hIL15 mice.

PUBLICATIONS
  • Shultz et al. (2005). Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells. J Immunol, 174(10): 6477–6489.
  • Seitz (2010). Establishment of a Rhabdomyosarcoma Xenograft Model in Human-Adapted Mice. Oncology Reports.
  • Wege et al. (2011). Humanized Tumor Mice: A New Model to Study and Manipulate the Immune Response in Advanced Cancer Therapy. Int J Cancer, 129(9): 2194–2206.
  • Ali et al. (2015). IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells. Front Immunol, 6:355.
  • Fehniger et al. (2001). Fatal Leukemia in Interleukin-15 Transgenic Mice Follows Early Expansions in Natural Killer and Memory Phenotype CD8⁺ T Cells. J Exp Med, 193: 219–231.